Half Moon Bay, CA, United States of America

Alan G Olivero

USPTO Granted Patents = 46 

 

 

Average Co-Inventor Count = 8.2

ph-index = 10

Forward Citations = 344(Granted Patents)


Location History:

  • Half Moon Bay, CA (US) (2002 - 2021)
  • South San Francisco, CA (US) (2011 - 2023)

Company Filing History:


Years Active: 2002-2023

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Fused Ring Compounds
Tricyclic PI3K Inhibitor Compounds
Biheteroaryl Compounds
Phosphoinositide 3-Kinase Inhibitor Compounds
Benzoxazepin PI3K Inhibitor Compounds
Pyrazolo[1,5a]Pyrimidine Derivatives
Thiazolopyrimidine PI3K Inhibitor Compounds
RAF Inhibitor Compounds
Serine Protease Inhibitors
Benzofuran Inhibitors
Halo-Alkoxycarbonyl Prodrugs
Amidine Inhibitors
46 patents (USPTO):Explore Patents

Title: Alan G Olivero: A Pioneer in Pharmaceutical Innovations

Introduction: Alan G Olivero, based in Half Moon Bay, California, is a distinguished inventor with an impressive portfolio of 46 patents. His groundbreaking work primarily focuses on the development of innovative compounds aimed at addressing critical health challenges, particularly in the field of oncology.

Latest Patents: Among his notable patents are the fused ring compounds targeting the inhibition of Ras proteins, described in formulations that hold promise for cancer treatments. Specifically, these compounds are detailed in formulas (I), (II), and (III), showcasing their potential applications in medical therapies. Additionally, Olivero has developed a process for the preparation of tricyclic PI3K inhibitor compounds, which emphasizes high yield and purity in aqueous solvent systems, further advancing the methodologies for treating cancer.

Career Highlights: Olivero has significantly contributed to the pharmaceutical industry through his roles at leading companies, including Genentech, Inc. and F. Hoffmann-La Roche AG. His expertise and innovative spirit have enabled him to develop therapies that impact patient care and treatment methodologies.

Collaborations: Throughout his career, Olivero has had the opportunity to collaborate with talented individuals such as Adrian Folkes and Steven T Staben. These partnerships not only exemplify the synergy often seen in research and development but also highlight the collaborative nature of innovation in the pharmaceutical sector.

Conclusion: Alan G Olivero's contributions to the field of pharmaceuticals exemplify the essence of innovation and dedication to improving health outcomes. With his extensive patent portfolio and collaborative spirit, he continues to be a significant figure in the advancement of medical treatments, showcasing the important intersection of invention and healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…